Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
On any given day, the show will cover at least 20 stocks determined by co-hosts Joel Elconin and Dennis Dick along with producer Spencer Israel.
Traders, investors and especially algorithms are keying on pharma or biotech stocks that may play a role in developing testing kits, vaccines or even a cure for the coronavirus.
One issue that attracted a buying frenzy in after-hours trading on Friday and in premarket trading Monday was Abbott Labs ABT.
FDA Authorizes Fast-Acting Test To Detect COVID-19
On Friday evening well after the close, Abbott announced that the FDA issued an Emergency Use Authorization for the fastest available molecular point-of-care test for the detection of COVID-19. An added bonus: the test delivers positive results in as little as 5 minutes and negative results in 13 minutes.
Traders, Algorithms Nibble On The News, Then Gorge
With limited liquidity in the closing hour or so of the after-hours session, the issue moved from the $74 area to as high as $77 before ending the session at $76.35.
As the news circulated on the wires over the weekend, the issue opened sharply higher at 4 a.m. Monday at $84.95 and continued in that direction on heavy volume. It did not peak until it came within striking distance of its all-time-high ($92.45), reaching $91.50. At that point, the big sellers came in and began to take profits.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
How Much Will Abbott's Test Have An Impact On Earnings?
It is hard to deny that the test will be a positive for the company and will have a positive impact on its futures earnings. PreMarket Prep co-host Dennis Dick questioned the degree of that impact.
While the issue was being discussed on the show Monday, it was trading in the $87 area. Dick said that adding $30 billion in market cap to a $131-billion company overnight was overdone.
He said he was hoping to short the issue in the $90 area, but was never afforded the opportunity.
The stock was trading 7.32% higher at $80.02 at the time of publication.
Abbott Moving Forward
Investors that are long the issue should pay close attention to Monday's price action, including the high, low and close. It is imperative that the issue continues to make new daily high and closes to push itself back toward its all-time-high.
If today’s low of $78.47 is breached, there may be limited support in the issue until Friday’s closing price of $74.56.
Photo courtesy of Abbott.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.